IMCR
IMCR clinical trials: Immunocore Holdings plc
Every trial on ClinicalTrials.gov where Immunocore Holdings plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 15
- As lead sponsor
- 6
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
IMCR on the catalyst calendar · IMCR registry changes
- Primary completion Oct 13, 2020ActualPhase 2NCT03070392Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaImmunocore Ltd · Uveal MelanomaCompletedIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2030Sponsor estimatePhase 1NCT07493122Study of IMC-S118AI in Type 1 DiabetesImmunocore Ltd · Type 1 DiabetesNot yet recruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 1/Phase 2NCT04262466Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsImmunocore Ltd · Select Advanced Solid TumorsActive, not recruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT07156136Study of IMC-P115C in Advanced PRAME-Positive CancersImmunocore Ltd · PRAME PositiveRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2027Sponsor estimatePhase 3NCT06112314IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Immunocore Ltd · Advanced MelanomaRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 3NCT05549297Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Immunocore Ltd · Advanced MelanomaRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced CancersImmunocore Ltd · CancerRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2023Sponsor estimatePhase 1/Phase 2NCT03973333Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabImmunocore Ltd · Select Advanced Solid TumorsWithdrawnIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2024Sponsor estimatePhase 1NCT05867056Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV InfectionImmunocore Ltd · Hepatitis B, ChronicWithdrawnIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2023ActualPhase 1/Phase 2NCT02535078Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaImmunocore Ltd · Malignant MelanomaWithdrawnIMCRLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2020ActualPhase 1/Phase 2NCT02570308A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaImmunocore Ltd · Uveal MelanomaCompletedIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2021ActualPhase 1/Phase 2NCT03515551Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive CancersImmunocore Ltd · Select Advanced Solid TumorsTerminatedIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04960891A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspImmunocore Ltd · Uveal MelanomaAvailableIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2019ActualPhase 2NCT02889861IMCgp100-401 Rollover StudyImmunocore Ltd · Malignant MelanomaTerminatedIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2016ActualPhase 1NCT01211262Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant MelanomaImmunocore Ltd · Malignant MelanomaCompletedIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2NCT06414590Neoadjuvant Tebentafusp for Uveal MelanomaThomas Jefferson University · Locally Advanced Unresectable Uveal MelanomaRecruitingIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07803562Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspUniversity of California, San Diego · Uveal Melanoma, MetastaticWithdrawnIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2028Sponsor estimatePhase 2NCT06070012Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaDiwakar Davar · Uveal MelanomaRecruitingIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2032Sponsor estimatePhase 3NCT06246149Adjuvant Tebentafusp in High Risk Ocular MelanomaEuropean Organisation for Research and Treatment of Cancer - EORTC · Uveal MelanomaRecruitingIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2028Sponsor estimatePhase 2NCT06627244Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaUniversity of Miami · Metastatic Uveal MelanomaRecruitingIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT05315258Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaUniversity of Oxford · Melanoma (Skin)Active, not recruitingIMCRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner